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Cirrhosis  due  to  hepatitis  C  (HCV)  infection,  with  or  without  hepatocellular  carcinoma  (HCC),  
is  the  leading  indication  for   liver  transplantation  (LT)  worldwide.  Recurrent  HCV  infection  of  
the  allograft  is  universal  if  the  virus  is  detectable  at  the  time  of  transplant,  with  variable  clinical  
course.   In  one   third  of   liver   recipients   recurrent  HCV   infection   lead   to  cirrhosis   in   the  graft  
within  only  5   years  after  LT.  A  small   proportion  of   recipients   can  develop  cholestatic  HCV  
(CHC),  a  severe  form  of  recurrence  carrying  a  poor  prognosis.  In  the  last  years,  the  approval  
of  interferon-­free  (IFN-­free)  regimens  for  the  treatment  of  chronic  HCV  has  been  a  major  step  
forward  in  Transplant  Hepatology.  The  safety  and  efficacy  of  direct  acting  antivirals  (DAAs)  
allow  to  treat  patients  awaiting  LT  as  well  as  individuals  with  HCV  recurrence  after  LT.  Here  
we  present  two  studies  including  HCV-­infected  patients  in  the  peri-­transplant  setting.  In  the  
first  study  we  aimed  to  assess  the  persistence  of  HCV-­RNA  in  liver  explants  of  HCV-­infected  
patients  treated  with  an  IFN-­free  regimen  on  the  waitlist  for  LT,  and  to  analyze  if  its  presence  
was  associated  with  relapse  after  LT.  Moreover,  we  investigated  the  potential  role  of  the  innate  
immune   response   on   the   persistence   of   HCV-­RNA   in   the   liver.   Residual   HCV-­RNA   was  
detected  in   liver  explant   in  67%  of  HCV-­infected  patients  treated  with  DAAs  on  the  waitlist,  
and  with  serum  HCV-­RNA  negative  at  transplant.  Nevertheless,  HCV-­RNA  persistence  in  liver  
explant  does  not  seem  to  be  associated  with  virological  relapse  after  transplantation,  except  
in  cases  where  liver  HCV-­RNA  concentrations  are  high.  Interestingly,  we  also  found  that  the  
intrahepatic  IFN  pathway  is  down-­regulated  in  patients  treated  with  DAAs.  
In  the  second  study  we  investigated  virological  mechanisms  involved  in  the  pathogenesis  of  
cholestatic  HCV  (CHC)  after  LT,  assessing  the  HCV  quasispecies  evolution  and  presence  of  
specific   mutations   within   the   NS5B   region,   before   and   after   LT,   using   ultra-­deep  
pyrosequencing.  Patients  included  in  this  study  were  at  the  extreme  spectrum  of  hepatitis  C  
recurrence:  mild  disease  with  an  excellent  long-­term  outcome  and  patients  with  CHC  with  a  
poor  outcome.  We  showed  that  in  patients  with  CHC,  the  predominant  virus  strain  outgrow  the  
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others  and  generates  a   relatively  uniform  quasispecies.   In   these  patients,  HCV  appears   to  
acquire  an  increased  fitness  in  the  new  graft,  since  we  found  that  the  master  sequence  present  
before  LT  propagated   in  most  of  CHC  patients  after  LT,  but  not   in  patients  with  mild  HCV  
recurrence.  We  cannot  exclude  that  specific  mutations  within  HCV  genome  of  patients  with  
CHC  may  explain   the  high  viral   replication  capacity  and   fitness.   Indeed,  we   found  specific  
mutations  in  the  HCV  genome  of  some  patients  with  CHC,  but  our  sample  was  not  sized  to  
show  significant  differences  with   individuals  with  mild  hepatitis  C  recurrence.  A  further  step  
forward  could  be  to  introduce  these  mutations  in  in  vitro  models  to  test  their  impact  on  virus  
replication/fitness.  
  
In   conclusion,   the   antiviral   treatment   of   hepatitis   C   infection   with   DAAs   before   liver  
transplantation   seems   the   ideal   option   in   the   liver   transplant   setting.   However,   in   patients  
treated  with  DAAs  on  the  waiting  list,  who  have  high  explant  HCV-­RNA  concentrations  and  a  
downregulation  of   IFN-­pathway,  another   therapeutic  strategy  should  be  choose   in  order   to  
avoid  HCV  recurrence  after  LT.    
In   patients   who   develop   a   cholestatic   hepatitis   C   recurrence   after   LT,   the   application      of  
specific  mutations  of  HCV  polymerase  gene   in   in  vitro  models  might  be  crucial   for  a  better  










La   cirrosi   epatica   dovuta   all’infezione   dell’epatite   C   (HCV),   associata   o   meno   ad  
epatocarcinoma,  è  l’indicazione  principale  al  trapianto  di  fegato.  La  ricorrenza  dell’infezione  
nel  fegato  trapiantato  è  universale  nei  pazienti  HCV  positivi  al  momento  del  trapianto.  Un  terzo  
dei  riceventi  presenta  un  quadro  cirrosi  epatica  nei  5  anni  successivi  al  trapianto  di  fegato  e  
una  parte  minore  può  sviluppare  una  forma  severa  di  ricorrenza,  associata  ad  una  prognosi  
infausta,   chiamata   epatite   colestasica   fibrosante   (CHC).      Negli   ultimi   anni,   l’utilizzo   delle  
terapie  antivirali  senza  interferone  per   il   trattamento  dell’epatite  C  ha  segnato  un  traguardo  
importante  dell’epatologia  dei  trapianti.  Infatti  l’efficacia  e  la  sicurezza  dei  farmaci  antivirali  ad  
azione  diretta  (DAAs)  permette  di  trattare  i  pazienti  con  cirrosi  HCV-­correlata  in  lista  d’attesa  
per  trapianto  e  i  pazienti  trapiantati  che  hanno  sviluppato  una  ricorrenza  dell’infezione  dopo  
trapianto.  In  questa  tesi  presentiamo  due  studi  che  includono  pazienti  affetti  da  epatite  HCV  
nell’ambito  del  trapianto  di  fegato.  Nel  primo  studio  lo  scopo  è  stato  quello  di  determinare  la  
persistenza  del  genoma  virale  (HCV-­RNA)  nel  fegato  espiantato  di  pazienti  con  cirrosi  HCV-­
correlata,  che  avevano  ricevuto  un  trattamento  antivirale  con  DAAs,  durante  la  lista  d’attesa  
per  trapianto  di  fegato.  Abbiamo  inoltre  valutato  il  ruolo  dell’immunità  innata  nella  persistenza  
dell’HCV-­RNA   nel   fegato   espiantato   dopo   trattamento   antivirale.   Abbiamo   dimostrato   che,  
nonostante  il  trattamento,  il  genoma  virale  persisteva  nel  fegato  espiantato  della  maggior  parte  
dei   pazienti.   Tuttavia,   la   presenza   di   HCV-­RNA   non   è   risultata   associata   al   fallimento   del  
trattamento,  ossia  alla  ricorrenza  dell’infezione  HCV  dopo  trapianto,  tranne  che  nei  pazienti  in  
cui  vi  era  una  elevata  quantità  di  genoma  virale  nel   fegato  espiantato.   Interessante  è  stato  
vedere  come  in  questi  pazienti  trattati  con  DAAs  ci  fosse  una  ridotta  attivazione  della  via  di  
segnalizzazione  cellulare  dell’interferone.        
Nel   secondo   studio   sono   stati   indagati   specifici   meccanismi   virologici   coinvolti   nella  
patogenesi  dell’epatite  colestasica  C  (CHC),  la  forma  più  severa  di  ricorrenza  dell’epatite  C  
dopo  trapianto  di  fegato.  L’evoluzione  delle  popolazioni  virali  che  circolano  normalmente  in  un  
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unico   individuo,   chiamate   quasispecie   virali,   e   la   presenza   di   specifiche   mutazioni   nella  
regione   codificante   per   la   polimerasi   del   virus   (NS5B)   sono   state   studiate   utilizzando   una  
tecnica  molto  sensibile  e  innovativa,  quale  il  sequenziamento  massivo  di  nuova  generazione.  
Sono  stati  inclusi  nello  studio  due  gruppi  di  pazienti:  pazienti  che  avevano  sviluppato  la  CHC  
e  pazienti  che  avevano  presentato  una  forma  lieve  di  ricorrenza  dell’epatite  C  dopo  trapianto,  
inclusi  nel  gruppo  di  controllo.  Abbiamo  visto  che  nei  pazienti  con  CHC  uno  specifico  ceppo  
virale  dominava  sugli  altri,  generando  una  quasispecie  virale  omogenea.  In  questi  pazienti  il  
virus  aveva  acquisito   una  maggiore   “fitness”,   confermato  anche  dal   fatto   che   la   sequenza  
maggioritaria  presente  prima  del   trapianto  si  manteneva  anche  dopo   trapianto.   Invece,  nei  
pazienti  con  una  ricorrenza  lieve  questo  non  avveniva,  e   la  quasispecie  virale  appariva  più  
disomogenea  dopo  trapianto.  Nei  pazienti  con  CHC,  la  presenza  di  specifiche  mutazioni  del  
gene   NS5B   potrebbero   spiegare   il   comportamento   del   virus,   che   replicando   ad   alti   livelli  
induce  un  danno  cellulare  severo.  Abbiamo  identificato  alcune  mutazioni  della  regione  NS5B  
nei      pazienti   con  CHC  ma,  probabilmente  per   il   piccolo   campione   incluso  nello   studio,   tali  
mutazioni  non  erano  significativamente  più  presenti  nei  pazienti  con  CHC  rispetto  al  gruppo  
di   controllo.  L’obiettivo  successivo  sarà  quello  di  utilizzare  queste  mutazioni  per   creare  un  
modello   in  vitro,  che  permetta  di  confermare   il   loro   impatto  sulla   replicazione  del  virus  e   la  
patogenesi  della  CHC.    
In  conclusione,  in  pazienti  trattati  con  i  nuovi  potenti  farmaci  antivirali  durante  la  lista  d’attesa  
per  trapianto,  che  presentano  alti  livelli  di  HCV-­RNA  nell’espianto  e  con  una  ridotta  risposta  
immunitaria  innata,  dovrebbe  essere  adottata  un’altra  strategia  terapeutica  dopo  trapianto.    
Nei  pazienti  che  sviluppano  una  epatite  colestatica  HCV  correlata  dopo  trapianto  di  fegato,  lo  
studio  e   l’utilizzo  di  mutazioni  presenti  nel  genoma  virale  possono  essere  utili  allo  scopo  di  
definire   i   meccanismi   alla   base   di   questa   severa   forma   di   ricorrenza   dell’epatite   C   dopo  
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1.   GENERAL   INTRODUCTION:   HEPATITIS   C   INFECTION   IN   THE   LIVER  
TRANSPLANT  SETTING  
  
Cirrhosis  secondary   to  chronic  hepatitis  C   (HCV),  with  or  without  hepatocellular  carcinoma  
(HCC),  is  the  leading  indication  for  liver  transplantation  (LT)  worldwide  (1,2).  Recurrent  HCV  
infection   of   the   allograft   is   universal   if   the   virus   is   detectable   at   the  moment   of   transplant  
surgery.  One  of  the  main  characteristics  of  HCV  recurrence  after  LT  is  the  accelerated  course  
of  the  disease  when  compared  to  immunocompetent  patients.  Approximately  one  third  of  liver  
recipients   will   progress   to   liver   cirrhosis   in   the   graft   within   only   5   years   after   LT.   This  
accelerated  fibrosis  rate  impacts  both  the  allograft  and  recipient  survival,  which  is  significantly  
reduced  when  compared  with  non-­HCV  liver  recipients,  as  reported  by  several  large  registry  
analyses   (3).  During   transplantation,   the  HCV-­infected   liver   is   removed  and   replaced  by  a  
graft,  so  consequently,  serum  HCV  RNA  decreases  dramatically,  even  disappears,   in  most  
patients  after  transplantation.    Despite  this  initial  decrease,  there  may  be  a  rapid  increase  in  
HCV  viral  load  within  hours  after  graft  reperfusion,  and  the  serum  HCV  load  may  reach  pre-­
transplantation   levels   in   only   a   few   days.   Acute   hepatitis   (biochemical   and   histological)  
generally  occurs  in  the  first  3–4  months,  before  the  establishment  of  chronic  hepatitis  and  its  
sequelae  (4,5).  The  clinical  outcome  of  recurrent  HCV  infection  after  LT  may  be  variable,  and  
depends  of  (or   is  related  to)  several   factors   that   take  place   in   the  first  period  after  LT.  The  
presence  of  significant  fibrosis  (fibrosis  stage  ≥  2)  or  significant  portal  hypertension  (HVPG≥  
6  mmHg)  in  the  graft  1  year  after  LT  identifies  patients  with  severe  HCV  recurrence  (6-­10).  
These  patients,  defined  as  “rapid  fibrosers”,  have  a  higher  risk  of  clinical  decompensations  
than  patients  with  lower  stages  of  fibrosis  and  normal  portal  pressure  at  the  same  time  point.  
A  very  severe  form  of  HCV  recurrence,  fortunately  uncommon,  is  called  cholestatic  HCV  that  
is  characterized  by  marked  cholestasis  with  or  without  cirrhosis  or  rapidly  expanding  sinusoidal  
fibrosis,  leading  to  high  risk  of  liver  failure  and  mortality  (11-­14).  Early  recognition  of  CHC  is  
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crucial      to      its      successful   treatment.  Very   little   is  still   known  about   the  pathophysiology  of  
cholestatic  hepatitis  C  recurrence  and  the  ways  in  which  it  differs  from  other  more  conventional  
forms  of  aggressive  hepatitis  C.    
In  the  last  years,  the  approval  of  interferon-­free  regimens  for  the  treatment  of  chronic  hepatitis  
C   has   been   a   major   step   forward   in   Hepatology   (15-­27).   The   safety   and   efficacy   of   the  
combination   of   several   direct   acting   antivirals   (DAAs),   compared   to   interferon-­containing  
regimens,  has  opened  hope  for  groups  of  patients  in  whom  interferon-­based  regimens  were  
contraindicated  or   in  whom  these  regimens  had  a  very   limited  efficacy  and  poor   tolerance:  
patients   awaiting   liver   transplantation   and   individuals   with   hepatitis   C   recurrence   after  
transplantation.  The  results  from  clinical  trials  and  real-­life  cohort  showed  sustained  virological  
response  rates  (SVR)  up  to  90%  along  with  high  safety  profile  in  cirrhotic  patients  and  in  liver  
recipients   (15-­27).  The  aim  of   the   treatment  during   the  waiting   list   is   to  achieve  HCV-­RNA  
negative  or  SVR  before  LT  to  avoid  HCV  infection  of  the  graft.  On  the  other  hand,  the  main  
goal  of  treating  HCV  infection  in  transplanted  patients  is  to  prevent  liver  injury  related  to  HCV  
recurrence,  finally  improving  both  patient  and  graft  survival  when  virus  eradication  is  achieved  
(28).  
Here  we  present  2  studies  including  patients  in  the  2  different  scenario  of  HCV  infection:  before  
and   after   liver   transplantation.   In   the   first   study  we   evaluated   virological   and   host-­   related  
features   in   HCV-­infected   cirrhotic   patients   awaiting   a   transplant,   undergoing   an   IFN-­free  
regimens  during  the  waiting  list.  In  the  second  study  we  investigated  virological  mechanisms  







2.   RESIDUAL  HCV-­RNA   IN   LIVER  EXPLANTS  OF  PATIENTS  AWAITING   LIVER  
TRANSPLANTATION  TREATED  WITH  AN  INTERFERON-­FREE  REGIMEN    
 
2.1.  Background  and  aims  
The   introduction   of   DAAs   in   the   hepatitis   C   armamentarium   has   completely   changed   the  
management  of  patients  with  chronic  HCV  infection,  particularly  in  the  peri-­transplant  setting.  
The  main  goal   of   treatment   in  patients  awaiting  a  LT   is   to  prevent  HCV  graft   infection,   by  
eradicating  the  virus  in  the  serum  and  liver  (28).  A  full  treatment  course  is  not  always  possible  
before  transplantation,  as  waiting  time  is  unpredictable.  Fortunately,  patients  treated  with  the  
available  IFN-­free  regimens  have  rapid  declines  in  viral  load,  with  most  achieving  undetectable  
serum  HCV-­RNA  within  4  weeks  of   the   initiation  of   therapy   (18).  However,   the  duration  of  
treatment  necessary  to  clear  HCV  from  infected  liver  cells  in  patients  with  advanced  cirrhosis  
using  IFN-­free  regimens  is  unknown.  Indeed,  the  only  data  assessing  the  persistence  of  HCV-­
RNA  in  liver  explants  of  patients  treated  while  on  the  waiting  list  are  from  the  IFN  era  (29).    
The  main   purpose   of   the   present   study  was   to   assess   the   presence   of  HCV-­RNA   in   liver  
explants  of  HCV-­infected  patients  treated  with  an  IFN-­free  regimen  on  the  waitlist  for  LT,  and  
to  analyze  if  its  presence  was  associated  with  relapse  after  LT.  Secondarily,  we  investigated  
the  potential  role  of  the  innate  immune  response  on  the  persistence  of  HCV-­RNA  in  the  liver,  
by  analyzing  the  intrahepatic  expression  of  specific  interferon-­stimulated  genes  (ISGs).    
  
2.2.  Patients  and  methods  
2.2.1.  Patient  population  and  collected  data  
We  enrolled  patients  who  had  received  an  IFN-­free  regimen  while  on  the  waiting  list  for  LT  
with  an  available  explanted  liver.  Patients  who  achieved  SVR  before  LT,  those  with  detectable  
HCV-­RNA  in  serum  at  time  of  transplantation,  and  those  who  died  after  LT  without  reaching  
enough   follow-­up   to   assess   a  SVR   (see   below)  were   excluded.   The   following   clinical   and  
virological  variables  were  recorded:  demographical,  treatment  regimen  and  duration,  baseline  
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viral  load  and  HCV-­RNA  concentrations  during  treatment  and  at  time  of  LT,  HCV  genotype,  
recipient  IL28B  genotype,  liver  disease  severity  scores  (MELD  and  Child-­Pugh  scores).  The  
study  was  approved  by  the  Ethical  Committee  of  the  Hospital  Clínic  of  Barcelona  and  by  the  
institutional   review   board   or   independent   ethics   committees   at   participating   sites;;   patients  
gave  written  inform  consent.  The  study  was  conducted  in  compliance  with  the  Declaration  of  
Helsinki,  Good  Clinical   Practice   guidelines,   and   local   regulatory   requirements   (for   patients  
included  in  the  2  clinical  trials).    
  
2.2.2.  Antiviral  treatment  regimens  
Patients  received  different  IFN-­free  regimens:  1)  Patients  included  in  a  phase  2,  open-­label,  
pilot  study  received  SOF  administered  orally  once  daily  at  a  dose  of  400  mg,  along  with  RBV  
administered  orally  as  a  divided  dose  according  to  body  weight.  The  treatment  durations  were  
24  or  48  weeks  (18);;    2)  patients  included  in  a  phase  3  clinical  study  received  ledipasvir  (LDV)  
and  SOF  administered  orally   once  daily   at   a   fixed-­dose   combination   (FDC)  of   90/400  mg,  
along  with  RBV   administered   orally   as   a   divided   dose   according   to   body  weight   and   liver  
disease  stage  for  12  or  24  weeks  (27);;  3)  patients  who  were  not  part  of  a  clinical  trial  underwent  
treatment  with  SOF  and  RBV  for  at  least  24  weeks,  SOF  plus  daclatasvir  (DCV)  60  mg  daily  
and  RBV  for  24  weeks,  or  SOF  plus  simeprevir  (SMV)  150  mg  daily  and  RBV,  for  12  weeks.  
RBV  was  administered  orally  as  a  divided  dose  according  to  body  weight  and  liver  disease  
stage  (starting  at  600  mg  if  clinical  decompensation  was  present).    
  
2.2.3.  Serum  HCV-­RNA  quantification  
Quantification   of   serum   HCV-­RNA   was   performed   by   COBAS®   Ampliprep®   HCV   Test.    
Sustained  virological  response  (SVR)  after  LT  (pTVR12)  was  defined  as  HCV-­RNA  target  not  
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detected  (TND)  (HCV-­RNA  <  15  IU/mL)  that  persisted  12  weeks  after  LT.  The  HCV  genotype  
was  determined  by  sequence  analysis  of  the  NS5B  region  of  the  HCV  genome.  
HCV-­RNA  extraction  and  quantification  from  liver  explant  tissue  
Tissue  samples  from  liver  explants  were  collected  at  the  time  of  LT  and  preserved  in  RNA-­
later  solution  (Qiagen,  Hilden,  Germany)  at  −80ºC  until  use.  Total  RNA  was  extracted  from  
20-­30   mg   of   starting   tissue   using   the   NucleoSpin®   RNA   II   kit   (Macherey-­Nagel,   Düren,  
Germany),   following   the   manufacturer’s   instructions.   After   tissue   disruption   and  
homogenization,  18  µl  of   IC  (Internal  Control,  Abbott  RealTime  HCV  assay)  were  added  to  
each  sample.  RNA  was  finally  eluted  in  88  µl  of  RNase-­free  water  and  stored  at  -­80°C  until  
the  quantification.  RNA  concentration  and  quality  were  assessed  with   the  NanoDrop  1000  
spectrophotometer  (ThermoScientific,  NanoDrop  products,  Wilmington,  DE)  and  the  RNA  was  
stored   at   -­80o   C.   HCV-­RNA   was   determined   using   the   Real-­Time   HCV   assay   (Abbott  
Molecular,  Des  Plaines,  IL)  and  the  Abbott  m2000rt  instrument.  Since  this  assay  is  intended  
for  serum  samples,  we  have  adapted  the  protocol  for  HCV-­RNA  quantification  for  liver  tissue  
samples.  HCV-­RNA  concentration   in   liver  was  expressed  as  copies  of  HCV-­RNA  per  µg  of  
total  RNA.    
 
2.2.4.  Assay  calibration  and  limit  of  HCV-­RNA  detection  
A  calibration  curve  was  generated  by  adding  known  serial  amounts  of  in  vitro  transcribed  HCV-­
RNA   (from   JFH1   isolate)   to   total   RNA   purified   from   HCV-­negative   liver   explant   samples  
(alcoholic   cirrhosis,   NASH   and   HBV-­related   cirrhosis).   The   HCV-­RNA   panel   ranged   from  
1x106   to   1x101   copies   per   reaction   and   each   panel   sample   was   tested   in   duplicate   (the  
average   measured   values   were   compared   with   the   expected   HCV-­RNA   levels).   The  
concentration  of  HCV-­RNA  in  a  tissue  sample  was  calculated  from  the  stored  calibration  curve  
and  expressed  as  HCV-­RNA  copies/µg  of  total  RNA.  In  order  to  evaluate  the  sensitivity  of  the  
assay,  serial  samples  containing  100  (n=  5),  20  (n=  6),  10  (n=  38),  5  (n=  26),  2.5  (n=  19),  1  
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(n=  30),  0.1  (n=  21)  HCV-­RNA  copies  were  tested.  Specificity  was  assessed  by  testing  56  liver  
samples  obtained   from  6  HCV-­negative  LT   recipients   (3  patients  with  alcoholic  cirrhosis,  2  
patients   with   HBV-­related   cirrhosis   and   1   patient   with   NASH).   The   limit   of   detection   was  
established  in  6  copies  per  reaction.      
 
2.2.5.  Relative  quantification  of  OAS1  and  MXA  genes  expression    
Relative  quantification  of  the  myxovirus  resistance  A  (MxA)  protein  and  2’–5’  oligoadenylate  
synthetase-­1  oligoadenylate  synthetase-­1  (OAS-­1)  gene  expression  was  performed  using  the  
Applied  Biosystems®  7500  Real-­Time  PCR  System  and  the  7500  software  v.2.0.1  (Applied  
Biosystems,  Carlsbad,  CA),  using  high  quality  RNA  extracted  from  liver  explant  samples  as  
explained   above.   The   FirstChoice®   Human   Liver   Total   RNA   (Life   Technologies,   Ambion,  
Carlsbad,  CA)  was  used  as  reference  for  target  genes  (OAS1  and  Mx1).  The  human  RPLP0  
(Large   Ribosomal   Protein)   gene   expression   was   used   as   endogenous   control.   Single-­
stranded   cDNA   from   200   ng   total   RNA   was   synthesized   using   the   High   Capacity   cDNA  
Reverse  Transcription  Kit  (Applied  Biosystems,  Carlsbad,  CA)  and  random  primers  according  
to  manufacturer´s  instructions.  The  assay  probes  for  OAS1  (Cat.  #  4331182,  FAM-­MGB),  Mx1  
(Cat.  #  4331182,  FAM-­MGB)  and  RPLP0  (Cat.  #  4310879E,  VIC®  -­TAMRA)  were  purchased  
from  ThermoFischer  Scientific  (Carlsbad,  CA).  Prior  to  relative  quantification  of  the  OAS1  and  
Mx1  genes,  an   initial  validation   relative  standard  curve   (CT  at  y-­axis,   linear  scale  vs.  RNA  
quantity  at  x-­axis,  log  scale)  was  performed  to  validate  the  PCR  efficiencies  of  the  OAS1,  Mx1,  
and  RPLP0  genes.  Quantitative  PCR  reactions  were  performed  using  the  SensiFAST™  Probe  
Lo-­ROX   Kit   (Bioline,   Singapore)   according   to   manufacturer´s   instructions.   Parallel   RNA  
standard  curves  were  obtained  for  the  3  above  mentioned  genes.  Therefore,  the  comparative  
CT  method  (the  ΔΔCT  method)  was  used  to  assess  the  relative  expression  of  the  OAS1  and  
Mx1  genes  in  each  liver  explant  sample.  Quantification  of  the  target  genes  OAS1  and  Mx1  
genes   were   performed   in   triplicate.   Final   data   are   expressed   as   mean   values   of   3  
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measurements  (±SD)  and  represent  the  relative  (fold)  gene  expression  of  the  OAS1  and  Mx1  
genes  in  each  liver  explant  sample  in  comparison  to  the  reference  RNA  mentioned  above  and  
are  corrected  to  the  endogenous  control  gene  expression.    
The  expression  of  the  OAS1  and  Mx1  genes  was  also  measured  in  2  control  groups:1)  patients  
with   detectable   HCV-­RNA   in   serum   at   time   of   LT   (n=13)   (8   non   treated   patients   and   5  
individuals  undergoing  an  IFN-­free  regimen),  2)  patients  with  undetectable  HCV-­RNA  in  serum  
who  were    receiving    an  IFN-­based  regimen  at  time  of  transplantation  (n=6).    
  
2.2.6.  Statistical  analysis  
Continuous   variables   are   depicted   using   median   and   interquartile   ranges   (IQR),   and  
categorical   variables   are   expressed   as   absolute   numbers   and   percentages.   Univariate  
analysis  was  performed  to  define  the  differences  in  clinical  and  virological  features  between  
positive  and  negative  explant  livers  and,  among  positive,  between  responders  and  relapsers.  
For   categorical   variables,   differences  between  groups  were  assessed  using  Fisher's  exact  
test,  while  differences  among  quantitative  variables  were  analyzed  with  Mann-­Whitney  test.  
Probit  analysis  has  been  used  to  determine  the  HCV-­RNA  limit  of  detection  of  the  Real-­time  
PCR.   All   differences   and   associations  were   considered   significant   at   a   2-­sided   p-­value   of  
<0.05.  Statistical  analyses  were  performed  with  SPSS,  version  18  (SPSS,  Chicago,  IL).    
 
2.3.  Results  
Liver  explants  were  available  from  48  patients  awaiting  a  liver  transplant  who  received  at  least  
1  dose  of  a  specific  IFN-­free  regimen:  38  patients  received  SOF  and  RBV  as  part  of  a  phase  
II  clinical  trial  (18),  6  patients  underwent  treatment  with  SOF/LDV  with  RBV  as  part  of  a  phase  
III  clinical   trial   (27)  and  4  patients   received  SOF  with  RBV  (n=1),  SOF  plus  DCV  and  RBV  
(n=2)  or  SOF  plus  SMV  and  RBV  (n=1),  as  part  of  a  real-­life  cohort  at  the  Liver  Unit,  Hospital  
Clinic   (Table   1).  Nine   of   these   48   patients  were   excluded   from   the   study   for   the   following  
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reasons:  death  before  the  post-­LT  12-­week  time  point  (n=3),  SVR12  achieved  before  LT  (n=2),  
detectable  serum  HCV-­RNA  at   the  moment  of   the   transplant  (n=4).  Thus,  39   liver  explants  
were  considered  for  the  final  analysis,  as  illustrated  in  Figure  1.    
The  clinical  and  virological  characteristics  of  patients  are  summarized  in  Table  1.  Seventy-­two  
percent  of  patients  were  male,  77%  were  infected  by  HCV  genotype  1,  and  nearly  80%  had  
non-­CC   IL28B   polymorphisms.   Twenty-­four   of   the   39   (62%)   patients   with   evaluable   liver  
explants  had  compensated  liver  cirrhosis  (Child-­Pugh  class  A).  The  median  MELD  score  was  
9.  The  median  treatment  duration  at  the  time  of  hepatectomy  for  LT  was  17  weeks  and  70%  
of  patients  had  serum  undetectable  HCV  RNA  by  the  third  week  of  treatment.    
  
2.3.1.  Persistence  of  HCV-­RNA  in  liver  explant    
HCV-­RNA  was  quantified   in   liver   explant   samples,   as   described   in  Patients   and  Methods.  
HCV-­RNA  was  detected  and  quantified  in  26  of  the  39  liver  explants  (67%)  whereas  it  was  
undetectable  in  the  remaining  13  (33%).  Comparing  patients  with  an  HCV-­RNA  positive  liver  
explant  and  patients  with  HCV-­RNA  negative  liver  explant,  the  first  group  received  a  shorter  
treatment   course   (14   vs   21   weeks,   respectively,   p=0.014)   and   remained   HCV-­RNA  
undetectable   in   serum   before   transplant   for   a   shorter   period   of   time   (61   vs   99   days,  
respectively,  p=0.013)  (Table  1).  Regarding  viral  kinetics,  time  to  reach  HCV-­RNA  target  not  
detected  (TND),  as  well  as  HCV-­RNA  viral  decay  slopes  (from  baseline  to  weeks  1,  2,  and  3)  
were  similar  in  the  2  groups.    
Thirty-­three  out  of  39  patients  (85%)  achieved  pTVR  and  6  patients  (15%)  presented  recurrent  
HCV   infection  after   LT.  HCV-­RNA  was  detected   in   liver   explants   from  22   (67%)  of   the  33  
responders  and  in  4  (67%)  of  the  6  relapsers.  Thus,  we  did  not  find  any  association  between  
the  persistence  of  HCV-­RNA  in  liver  explants  and  the  post-­transplant  HCV  recurrence  (Figure  
1).        
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Considering  only  those  26  patients  with  residual  HCV-­RNA  in  the  liver  explant,  the  intrahepatic  
HCV-­RNA   concentration   was   significantly   higher   in   those   who   relapsed   after   LT   (n=4)  
compared  to  patients  who  achieved  pTVR  (n=22),  (23  vs  3  copies/µg  total  RNA,  respectively,  
p=0.016)  (Table  2).  The  amount  of  residual  HCV-­RNA  in  the  liver  explant  was  not  significantly  
different  in  patients  with  Child-­Pugh  ≥B7  and  MELD  ≥12  compared  to  those  with  CTP  <B7  and  
MELD   <12,   respectively   (p=0.108   and   p=0.164,   respectively).   Explant   HCV-­RNA  
concentrations  did  not  differ  between   individuals   treated  with  SOF  and  RBV  and  those  few  
patients  who  received  more  than  one  DAA.    
  
2.3.2.  Intrahepatic  expression  of  MxA  and  OAS-­1  
As  expected,  among  patients  treated  with  an  IFN-­containing  regimen  (n=6),  the  expression  of  
ISGs  was  significantly  higher  than  in  the  other  groups  (Figure  2a  and  2b).  Similarly,  patients  
with  positive  serum  HCV-­RNA  at  time  of  transplant  (n=13,  including  non-­treated  patients  and  
patients  undergoing  an  IFN-­free  regimen)  had  a  significantly  higher  expression  of  both  MxA  
and  OAS1  compared  to  patients  with  undetectable  serum  HCV-­RNA  at  time  of  transplantation  
(n=39)   (Figure   2a   and   2b).   Among   patients   with   positive   serum   HCV-­RNA   at   time   of  
transplantation,  we  did  not  find  a  significant  correlation  between  the  viral  load  and  the  levels  
of  MxA  and  OAS1  within  the  liver  (r=0.5,  p=0.09  and  r=0.49,  p=0.1,  respectively).    
Interestingly,  among  our  study  cohort  (patients  with  undetectable  serum  HCV-­RNA  at  time  of  
LT),  the  intrahepatic  innate  immune  response,  as  measured  by  the  abundance  of  MxA  and  
OAS-­1  RNA,  was  similar  in  individuals  with  (n=24)  and  without  (n=13)  HCV-­RNA  in  the  liver  




2.3.3.  Analysis  of  NS5B  mutants  according  to  the  presence  of  HCV-­RNA  in  liver  
explants    
In  a  subgroup  of  30  patients  who  were  part  of  the  phase  II  clinical  trial  (18)  we  assessed  the  
presence  of  emergent  amino  acid  substitutions  within  the  NS5B  region,  in  serum,  at  baseline  
and  at  time  of  relapse,  by  population  sequencing  and  deep  sequencing  (18).  Essentially,  we  
were  interested  to  explore  if   the  distribution  of  mutants  within  this  region  was  similar  or  not  
between   patients   with   and   without   HCV-­RNA   in   the   explant   (Figure   4).   Resistance   to  
sofosbuvir  is  conferred  by  the  S282T  substitution  in  NS5B  (30).  S282T  was  not  detected  in  
any  of  the  patients  at  baseline  or  virologic  failure.  L159F  and  V321A  have  been  identified  as  
treatment  emergent  variants  associated  with  sofosbuvir  treatment  (31,32).  Interestingly,  3  out  
of  6  relapsers  had  L159F  detected  as  major  species  at  baseline  and  relapse,  whereas  this  
variant  was   not   present   in   any   of   the   responder   patients.  RBV  associated   variants   T390I,  
F415Y  were  present  at  baseline  in  3  patients  with  detectable  HCV-­RNA  in  liver  explants  but  
were  not  detectable  at  relapse  time  point  (Figure  4).    In  the  2  relapsers  with  a  negative  HCV-­
RNA  explant  these  polymorphisms  were  present  as  double  or  triple  mutants  (Figure  4).    
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3.   VIROLOGICAL   FEATURES   IMPLICATED   IN   THE   DEVELOPMENT   OF  
CHOLESTATIC  HEPATITIS  C  AFTER  LIVER  TRANSPLANTATION  
 
3.1.  Background  and  aims    
An  uncommon  and  severe  variant  of  hepatitis  C  recurrence  after  liver  transplantation  (LT)  is  a  
cholestatic  graft  injury  termed  cholestatic  hepatitis  C  (CHC),  usually  present  between  3  to  6  
months  after  LT  (11-­14).  CHC,  whose  frequency  ranges  between  2%  and  14%,   is   typically  
characterized   by   marked   cholestasis   and   rapid   progression   to   graft   failure.   Patients   who  
develop   CHC   have   among   the   highest   viral   loads   in   serum   and   liver,   with   levels   of   viral  
replication  significantly  higher  than  in  the  non-­immunosuppressed  state.  The  ILTS  Consensus  
Conference  in  2002  defined  CHC  using  several  features  that  should  be  present  to  make  the  
diagnosis  (11).  Variables  that  may  influence  the  progression  of  disease  include,  but  are  not  
limited   to,  HCV-­RNA   level  at   the   time  of  LT,  amount  of  administered   immune  suppression,  
type  of  immunosuppression,  early  histological  changes  of  the  allograft  and  donor  age.  In  the  
IFN-­era,  many  patients  with  CHC  were  too  sick  to  be  considered  eligible  for  antiviral  treatment  
based  on  Peg-­IFN  and  RBV,  or  they  had  to  stop  therapy  earlier  due  to  side  effects.  Fortunately,  
the   use   of   new  DAAs,   particularly   in   IFN-­free   regimens,   has   drastically   changed   the   poor  
prognosis   of   this   severe   form   of   hepatitis   C   recurrence   (33).   Results   from   several   clinical  
studies,  using  different  combinations  of  DAAs   in  CHC  patients,   reported  curative   response  
rate  up  to  100%  (17).  In  these  patients  severe  alteration  of  liver  tests  (bilirubin,  albumin,  INR)  
returned  to  normal  a  few  weeks  after  treatment  initiation  and  viral  clearance.  Despite  the  fact  
that  most  DAAs  did  not  show  clinically  significant  interactions  with  immunosuppressive  drugs  
(Cyclosporine  and  Tacrolimus),  an  antiviral  treatment  within  the  first  6  months  after  LT  might  
be   difficult   to   manage.   Indeed,   early   after   LT,   patients   are   still   under   strong  
immunosuppression,  at  risk  of  opportunistic  infections,  not  uncommonly  recovering  or  being  
treated  from  surgical  complications  and  undergoing  treatment  with  multiple  drugs.    
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There  is  still  a  limited  understanding  of  the  mechanisms  leading  to  the  development  of  CHC  
(34).   Hepatocellular   injury   in   CHC   is   believed   to   be   a   cytopathic   effect   of   HCV   which,  
replicating  at  high  level,  directly  induces  cellular  degeneration  in  a  short  period  of  time,  causing  
progressive  and  rapid  liver  failure.  Since  HCV  is  a  highly  replicative  virus,  in  each  replication  
cycle,  every  possible  point  mutation  and  many  double  mutations  are  generated  and  may  be  
present  within  the  virus  population  at  any  time.  HCV  exists  as  a  heterogeneous  population  of  
viral   quasispecies,   defined   as   a   number   of   closely   related   yet   unique   genomic   RNA   viral  
sequences  produced  over  time  in  an  individual  (35,36).  Sequencing  of  multiple  clones  of  HCV  
cDNA  has  shown  that  the  composition  of  the  HCV  quasispecies  changes  after  LT.  The  role  of  
complexity  and  diversity  of  viral  quasispecies  in  the  pathogenesis  of  HCV  recurrence  after  LT  
has   been   investigated   in   previous   studies,   showing   controversial   results   (37-­40).   The  
contradictory   results   in   the   literature  could  be  explained  by   the  use  of  different   techniques  
assessing  viral  quasispecies,  variability  in  those  methods  evaluating  quasispecies  complexity,  
diversity,  and  divergence,  and  to  the  heterogeneity  of  patients’  characteristics.  Of  the  above  
mentioned  limitations,  it  is  important  to  state  that  the  methods  used  to  study  HCV  quasispecies  
in   LT   setting   were   suboptimal,   limiting   the   possibility   to   describe   low   frequency   viral  
populations   and   to   detect   mutations   potentially   implicated   in   the   development   of   CHC  
recurrence.   Therefore,   the   analysis   of   HCV   quasispecies   diversity   and   complexity   with   a  
sophisticated  methodology  can  be  relevant   to  better  understand   the  pathogenesis  of  CHC.  
We   hypothesized   that   the   genetic   evolution   of   the   HCV   region   encoding   for   the   NS5B  
polymerase,  and  the  selection/fixation  of  specific  mutations  in  the  HCV  non-­structural  regions  
might  be  implicated  in  the  pathogenesis  of  CHC,  explaining  the  high  virus  replication  in  CHC  
patients.    
Therefore,  the  aim  of  this  study  was  to  analyze  in  patients  with  CHC,  compared  to  a  control  
group  HCV  quasispecies  evolution  and  presence  of  specific  mutations  within  the  NS5B  region,  
before  and  after  LT,  using  ultra-­deep  pyrosequencing.  
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3.2.  Patients  and  methods  
3.2.1.  Patient  population  and  collected  data  
All   patients   with   end-­stage   liver   disease   or   hepatocellular   carcinoma   (HCC)   secondary   to  
chronic   hepatitis   C   infection   who   underwent   LT   at   Hospital   Clinic   of   Barcelona   between  
05/1999  and  03/2012  were  considered  for   this  study.  Patients  were  followed  by  a  standard  
protocol  and  relevant  variables  were  collected  prospectively  and  included  in  a  database,  after  
approval  by  the  Ethical  Committee  of  the  Hospital  Clínic  of  Barcelona.  All  patients  signed  an  
inform  consent   to   this  purpose.  Patients  with   the  diagnosis  of  CHC  were   included   in  CHC  
group  and  patients  with  mild  HCV  recurrence  were  included  in  the  control  group.  The  diagnosis  
of  CHC  was  performed  according  to  previous  published  criteria  (11):  bilirubin  >6  mg/dL,  GGT  
and  ALP  ≥  5  ULN,  very  high  serum  HCV-­RNA,  and  typical  histology  of  CHC  in  the  absence  of  
biliary/arterial  complications.  Mild  HCV  recurrence  was  defined  by  absent  or  minimal  fibrosis  
(F0-­F1)  or   liver  stiffness  measurement   (LSM)  below  8.7  kPa,  during  a   follow-­up  of  5  years  
after  LT.  No  patient  received  antiviral  therapy  during  the  study  period.  
Regarding  recipient  and  donor  variables,  we  considered:  recipient  age  and  gender,  donor  age,  
episodes  of  acute  graft  rejection  (including  episodes  requiring  prednisone-­based  treatment),  
biochemical  liver  tests  (bilirubin,  GGT  and  ALP)  within  3  months  after  LT,  immunosuppression  
(tacrolimus   or   cyclosporine),   recipient   IL28   polymorphisms,   HCV   genotype   and   viral   load  
before  and  after  LT  (1-­3  months  after  LT).    
Two  serum  samples  for  each  patient  were  used  (a  total  of  44  samples):  1  sample  taken  at  the  
moment  of  transplant  and  1  sample  obtained  between  months  1  and  3  after  LT  (in  patients  
with  CHC,  at  the  moment  of  the  highest  viral  load).  
  
3.2.2.  HCV-­NS5B  fragment  amplification  for  UDPS  
HCV  RNA  was  extracted  from  140  μL  of  serum  by  manual  RNA  extraction  using  the  QIAamp  
viral  RNA  minikit  (Qiagen,  Hilden,  Germany),  as  specified  by  the  manufacturer.  The  measures  
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to  prevent  contamination  suggested  by  Kwok  and  Higuchi  {Kwok,  1989  683  /id}  were  strictly  
applied.  RT-­PCR  was  performed  using  Transcriptor  One  Step  RT-­PCR  Kit   (Roche  Applied  
Science   Basel,   Switzerland),   using   20pmol   of   both   the   sense   primer   5Bo8254   (5'-­
CNTAYGAYACCMGNTGYTTTGACTC-­3')   and   the   antisense   primer   5Bo8707   (5'-­
TTNGADGAGCADGATGTWATBAGCTC-­3').  Reverse   transcription  was   performed   at   50ºC  
for  30  min  followed  by  a  2-­step  PCR  reaction  including:  denaturing  for  7  min  at  94ºC;;  a  first  
step  of  10  cycles  of  10  s  at  94ºC,  30  s  at  50ºC,  and  1  min  at  68ºC;;  a  second  step  of  25  cycles  
of  10  s  at  94ºC,  30s  at  50ºC  and  1  min  at  68ºC,  increasing  extension  time  5  s  per  cycle;;  a  final  
7-­min   step   at   68ºC.   Hemi-­Nested-­PCR  was   performed   using   FastStart   High   Fidelity   PCR  
System,  dNTPack  (Roche  Applied  Science  Basel,  Switzerland).  Briefly,  5μL  from  the  previous  
PCR  were   amplified   by   a   second   PCR   using   a   pair   of   primers   which   were   composed   by  
universal   M13   forward   (M13f)   and   M13   reverse   (M13r)   at   5'   ends   followed   by   a   specific  
fragment   (italic   face)   complementary  of   the  HCV  PCR  product   amplified   in   the   first   round.  
Nested-­PCR  conditions  were  the  following:  denaturing  for  2  min  at  95ºC;;  35  cycles  of  30  s  at  
95ºC,  30s  at  55ºC  and  1  min  at  72ºC;;  a  final  7-­min  step  at  72ºC.  
For  sample  identification,  the  final  product  of  the  hemi-­nested  amplification,  was  subjected  to  
15-­cycles   of   re-­amplification   using   primers   composed   by   a   complementary   universal   M13  
primer  (either  sense  or  antisense)  followed  by  a  Roche's  Validated  Multiplex  Identifier  (MID)  
and  with  oligoA  or  B  at  5'  or  3'  end  of  the  sense  or  antisense  primer,  respectively.  
Amplification   products   were   analyzed   by   1.8%   agarose   gel   electrophoresis   and   negative  
controls  (amplifications  in  the  absence  of  RNA)  were  included  in  parallel  to  ensure  the  absence  
of  contamination  by  template  nucleic  acids.  PCR  products  were  purified  using  the  QIAquick  
Gel   Extraction   kit   (Qiagen,   Valencia,   CA,   USA),   quantified   using   the   PicoGreen   assay  
(Invitrogen,  Carlsbad,  CA,  USA),  and  analyzed  for  quality  using  the  BioAnalyzer  DNA  1000  




3.2.3.  Ultra-­deep  pyrosequencing  and  data  treatment  
Massive  sequencing  was  performed  in  the  GS-­Junior  454/Roche  platform  (Roche,  Branford,  
CT   06405,   USA),   using   titanium   chemistry,   which   enables   sequencing   of   400-­   to   500-­nt  
fragments  (GS  Junior  Titanium  Sequencing  Kit),  following  manufacturer  recommendations.  
The  data  used  for  the  analysis  was  the  FASTA  files  obtained  from  the  454  GS  Junior  system’s  
software,  which  applies  stringent  quality  controls  on  each  sequenced  nucleotide  to  guarantee  
the  integrity  of  the  full  length  of  the  amplicon.  Briefly,  the  sequences  were  first  demultiplexed  
by   identifying  MID  and  specific  primer   for  each  strand,  and  quality   filtered  by  excluding  all  
haplotypes  with  more  than  two  Ns  (any  base),  three  gaps,  not  covering  the  full  amplicon,  or  
with   an  an   identity   below  67%   relative   to   the  master   sequence   (defined  here   as   the  most  
abundant  haplotype  in  the  corresponding  population).  The  accepted  haplotypes  with  Ns  and/or  
gaps  were  repaired  by  comparison  with  the  dominant  haplotype.  
  
3.2.4.  HCV  quasispecies  analysis  
The  quasispecies  complexity  of  each  sample  was  computed  based  on  the  haplotypes  common  
to   the   forward   and   reverse   strands   and   above   1%   of   abundance   after   the   quality   filter.  
Exclusion  of  haplotypes  present  at  frequencies  below  1%,  eliminates  from  the  analysis  both  
putative  artefactual  sequences  and  haplotypes  with  the  lowest  relative  fitness;;  the  procedure  
renders   the   most   frequent   sequences   at   each   time   point   for   comparison   purposes.   The  
computed  complexity  indices  were  the  nucleotide  diversity  defined  as  the  average  number  of  
differences   between   all   possible   haplotype   pairs,   corrected   by   their   frequencies   in   the  
population  and  the  mutation  frequency  defined  as  the  sum  of  the  differences  between  each  
haplotype  and  the  dominant  haplotype  (corrected  by  frequency).  
In  order  to  investigate  the  presence  of  specific  amino  acid  mutations  in  viral  population  that  
propagated   after   LT,   all  HCV-­NS5B   sequences   (before   and   after   LT)   from  both   groups   of  
patients  were  aligned  using  ClustalX.  
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3.2.5.  Statistical  analysis  
Continuous   variables   are   depicted   using   median   and   interquartile   ranges   (IQR),   and  
categorical   variables   are   expressed   as   absolute   numbers   and   percentages.      Univariate  
analysis  was  performed  to  define  the  differences  in  clinical  and  virological  features  between  
patients   with   CHC   and   patients   with   mild   HCV   recurrence   after   LT   (control   group).   For  
categorical  variables,  differences  between  groups  were  assessed  using  Fisher's  exact   test,  
while   differences   among   quantitative   variables  were   analyzed  with  Mann-­Whitney   test.   All  
differences   and   associations   were   considered   significant   at   a   2-­sided   p-­value   of   <0.05.  
Statistical  analyses  were  performed  with  SPSS,  version  18  (SPSS,  Chicago,  IL).    
  
3.3.  Results  
3.3.1.  Patients  characteristics  
During   the   study   period,   515   adult   patients   with   end   stage   liver   disease   related   to   HCV  
infection  underwent   liver   transplantation.  During   the   first   year  after  LT,  200  patients   (53%)  
were  classified  as  severe  hepatitis  C  recurrence,  either  by  the  presence  of  significant  fibrosis  
or   portal   hypertension   during   the   first   12   months   following   LT   or   by   the   occurrence   of   a  
cholestatic   hepatitis   C   or   severe   acute   hepatitis.   The   remaining   173   (46%)   patients   were  
classified   mild   hepatitis   C   recurrence.   Twenty-­two   patients   were   selected   for   the   study  
inclusion:   13   patients   with   a   diagnosis   of   CHC   and   9   patients   with   mild   HCV   recurrence  
(control  group).  Clinical  and  virological  characteristics  of  patients  are  summarized  in  Table  3.  
  
3.3.2.  Quasispecies  analysis  
At   time  of  LT,   the  quasispecies  diversity  and   the  mutation   frequency  were  similar  between  
patients  with  CHC  and  patients  with  mild  hepatitis  C  recurrence  (Fig  5a  and  5b).    
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After  LT,   the  genetic  diversity  decreased   in  both  groups  of  patients,  but   this  decrease  was  
more  pronounced  in  the  patients  with  cholestatic  hepatitis,  showing  a  marked  homogenization  
of  the  quasispecies  (Figure  6).  These  results  were  confirmed  by  the  mutation  frequency,  that  
significantly  decreased  after  LT  only  in  the  CHC  patients.  This  result  suggests  the  selection  of  
variants  more  similar  to  the  master  sequence,  and  probably  more  fitted  (Figure  7).  
Regarding  the  propagation  of  HCV  quasispecies  after  transplantation,  interestingly,  we  found  
that  in  the  majority  of  patients  with  CHC  (69%)  the  master  sequence  present  at  the  moment  
of  LT  propagated  efficiently  and  remained  as  the  dominant  sequence  after  LT.  This  behavior  
was  seen  in  only  1  patient  included  in  the  control  group  (11%)  (p=0.026)  (Figure  8a  and  8b).    
We  also  investigated  the  presence  of  amino  acid  mutations  analyzing  24  different  polymorphic  
sites  in  the  NS5B  region.  We  identified  9  amino  acid  mutations  present  in  both  groups  in  a  not  
significantly  different  proportion,  and  4  amino  acid  mutations  (N215S,  T267F,  C316N,  A246T)  

















Patients   with   HCV-­related   cirrhosis   awaiting   a   LT   were   one   of   the   most   difficult-­to-­treat  
populations   in   the   era   of   IFN-­based   antiviral   treatment.   This   scenario   has   dramatically  
changed  in  the  last  year,  as  patients  on  the  waitlist  for  LT  are  treated  with  more  efficacious  
and  safe  IFN-­free  regimens  (15-­17).  In  the  first  study  including  patients  who  received  IFN-­free  
therapy  during   the  waiting   list   for  LT   (18),   the  number  of  consecutive  days  with  HCV  RNA  
target  not  detected  (TND)  prior  to  transplant  has  been  identified  as  highly  predictive  of  post-­
transplant  virological  response  (pTVR),  According  to  these  study,  patients  awaiting  LT  should  
wait  at   least  30  days  after  serum  HCV-­RNA  clearance   to  prevent  HCV  graft   infection.  This  
rule,  however,   is  not  applicable   in   the   real-­life  as   the  waiting   time   is  unpredictable.  So   the  
question  is  if  all  HCV  patients  on  the  waiting  list  should  receive  antiviral  treatment,  because  
even   though   the   main   source   of   HCV   infection   (the   liver)   is   removed   at   transplant,   the  
persistence   of   residual   HCV-­RNA   in   liver   explants  might   impact   SVR   after   LT   in   patients  
undergoing   treatment  while   on   the  waitlist.   Since   there   are   no   studies   assessing   the   time  
required  to  clear  HCV  from  liver  cells   in  patients  undergoing  IFN-­free  therapy,  we  aimed  to  
assess  the  presence  of  HCV-­RNA  in  liver  explants  of  HCV-­infected  patients  treated  with  an  
IFN-­free  regimen  on  the  waitlist  for  LT.  In  our  study,  unexpectedly,  two  thirds  (67%)  of  patients  
had  residual  HCV-­RNA  in  their  liver  explants.  It  is  true  that  patients  with  HCV-­RNA  positive  
explants  received  a  shorter   treatment  course  and  remained  serum  HCV-­RNA  undetectable  
before   transplant   for   a   shorter   period   of   time   than   patients   with   HCV-­RNA   negative   liver  
explants.  Nevertheless,  there  was  a  substantial  proportion  of  individuals  with  residual  HCV-­
RNA  in  their  explants  who  had  cleared  HCV  from  serum  by  week  3  of  therapy  and  remained  
so  for  an  additional  number  of  weeks  (median  10)  before  transplantation.  This  is  a  novel  and  
unexpected  finding,  especially  considering  that  the  persistence  of  HCV-­RNA  in  liver  explants  
did  not  prevent  the  achievement  of  a  SVR  after  LT  in  the  majority  of  patients.    
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We   found   that   the   presence   of   HCV-­RNA   in   liver   explants   did   not   impact   on   virological  
response  after  LT,  however,  among  patients  with  residual  HCV-­RNA  in  the  liver,  there  was  a  
higher  amount  of  tissue  HCV-­RNA  in  those  who  relapsed  after  LT  compared  to  patients  who  
responded.  Despite  the  small  number  of  patients,  the  data  suggest  that  the  intrahepatic  levels  
of  HCV-­RNA  could  be  predictive  of  posttransplant  HCV  recurrence  among  patients  who  are  
serum  HCV-­RNA  negative  at   the   time  of   transplantation.     A  potential  explanation   is   that   in  
those  patients  with  higher  HCV-­RNA  concentrations  in  the  liver,  tiny  and  intermittent  amounts  
of  virions  (below  the  sensitivity  of  the  quantification  assays)  are  released  into  the  serum  and  
cause  a  virological  relapse  after  LT.  From  a  pathogenic  point  of  view,  we  cannot  exclude  that  
a  subpopulation  of  virus  can  persist  despite  of  antiviral  therapy.  Indeed,  the  sequestration  of  
HCV  genome  in  membranous  webs  may  be  a  potential  mechanism  by  which  the  virus  avoids  
degradation  and  clearance  from  hepatocytes  (41).  Some  data  support  the  idea  that  this  sort  
of  compartmentalization  protects  the  viral  RNA  from  host  defense  mechanisms,  leading  to  a  
small  fraction  of  HCV  RNA  to  persist  in  these  structures  despite  both  antiviral  therapy  and  host  
immune  responses.  The  integrity  of  HCV  genome  present  in  liver  explants  could  not  be  studied  
due  to  its  low  concentration  and  thus,  we  cannot  exclude  that  due  to  the  mechanism  of  action  
of  sofosbuvir  (chain  terminator),  the  residual  HCV-­RNA  found  in  the  liver  was  composed  of  
incomplete  HCV  genome  fragments.  
Our  findings  are  in  contrast  with  those  reported  for  a  cohort  of  HCV-­infected  patients  awaiting  
LT   undergoing   Peg-­IFN/RBV   therapy   who   had   undetectable   HCV-­RNA   at   time   of  
transplantation,  which  demonstrated  a  correlation  between  the  presence  of  residual  HCV-­RNA  
in  the  explant  and  HCV  recurrence  after  LT  (29).  HCV-­RNA  was  detected  in  the  liver  explants  
of  4  (80%)  out  of  5  relapsers,  but  only   in  2  (17%)  of  12  patients  who  achieved  pTVR.  The  
interferon  system   is  a  crucial  component  of   the   innate   immune  response  against  HCV  and  
exogenous  IFN  could  enhance  the  clearance  of  infected  liver  cells.  IFN  activity  is  mediated  by  
the  induction  of  intracellular  proteins,  such  as  the  MxA  protein  and  OAS-­1.  As  expected,  we  
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found  that  the  intrahepatic  expression  of  MxA  and  OAS-­1  was  significantly  higher  in  patients  
treated   with   IFN   (though   being   serum   HCV-­RNA   negative),   compared   to   patients   with  
undetectable   serum  HCV-­RNA   undergoing   an   IFN-­free   regimen.   The   stronger   exogenous  
induction  of  the  intrahepatic  IFN-­α  pathway  in  patients  undergoing  IFN  therapy  explains  this  
finding.  Intrahepatic  expression  of  MxA  and  OAS1  was  higher  in  individuals  with  detectable  
HCV-­RNA   in   serum   (reflecting   active   liver   HCV   replication)   compared   to   patients   with  
undetectable  serum  HCV-­RNA  who  were  undergoing  an  IFN-­free  treatment.  Moreover,  in  the  
latter  group,  the  intrahepatic  down-­regulation  of  the  IFN  pathway  was  seen  both  in  patients  
with  and  without  residual  HCV-­RNA  in  liver  explants.  Our  results  are  in  agreement  with  those  
recently   published   by  Meissner   et   al   (42),   who   demonstrated,   for   the   first   time,   that   HCV  
clearance   achieved   during   IFN-­free   treatment   with   SOF/RBV   is   accompanied   by   hepatic  
down-­regulation  of   type   II  and   III   IFNs,   their   receptors,  and   ISGs.  Down-­regulation  of   ISGs  
was   associated   with   on-­treatment   viral   suppression   and   occurred   regardless   of   treatment  
outcome,  since  all  patients  achieved  virologic  suppression  on  therapy.  However,  patients  who  
achieved  SVR  had  higher  intrahepatic  expression  of  ISGs  at  end-­of-­treatment  compared  with  
patients   who   relapsed.   The   authors   suggested   that   patients   able   to   reestablish   IFN  
homeostasis  by  the  end-­of-­treatment  may  be  more  likely  to  achieve  an  SVR,  whereas  patients  
who   fail   to   restore  homeostasis  may  be  more  prone   to  viral   relapse.  We  observed  a   lower  
amount   of   MxA   RNA   in   livers   from   patients   who   relapsed   after   transplantation,   but   the  
difference  did  not  reach  statistical  significance  (data  not  shown).    
In   conclusion,   in   this   study   we   demonstrated   that,   despite   the   use   of   effective   antiviral  
treatments,  residual  HCV-­RNA  remains  present  in  liver  explants  of  a  significant  proportion  of  
HCV-­infected   patients   treated   on   the   waitlist,   also   considering   that   the   intrahepatic   IFN  
pathway   is   down-­regulated   in   these   patients.   Nevertheless,   HCV-­RNA   persistence   in   liver  
explant  does  not  seem  to  be  associated  with  virological  relapse  after  transplantation,  except  
in  cases  where  liver  HCV-­RNA  concentrations  are  high.    
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A  proportion   of   patients  with   decompensated   cirrhosis   awaiting   a   LT   cannot   receive   a   full  
antiviral  treatment  before  transplant  (18).  In  some  of  them  is  even  not  possible  to  start  antiviral  
therapy  due  to  their  severe  clinical  status.  These  patients  should  wait  to  be  treated  after  LT  
(26).  Indeed,  several  studies  have  shown  excellent  safety  and  efficacy  results  of  DAAs-­based  
treatment  in  HCV-­infected  liver  transplant  recipients  (17).    
HCV  infection  is  accelerated  after  LT,  leading  to  worse  graft  and  patient  survival  in  patients  
undergoing  LT  for  HCV-­related  cirrhosis  than  in  those  transplanted  for  other  causes  (3,28).  
Disease  progression  is  highly  variable  and  while  some  patients  develop  cirrhosis  within  a  few  
years,   the   disease   remains   mild   and   does   not   progress   in   others.   The   mechanisms   that  
determine   these  outcomes  are  not  well  known,  although  a  complex   interplay  between  host  
and  viral  factors  is  probably  involved.  Cholestatic  hepatitis  C  constitutes  the  more  severe  form  
of  HCV  recurrence  with  almost  universal  mortality  (13).   It   is  typically  characterized  by  early  
HCV   recurrence  with  marked  cholestasis,   rapid   fibrosis  progression   leading   to  graft   failure  
within  the  first  1  to  2  years  after  transplantation.  Because  of  its  relatively  low  frequency,  only  
scarce  clinical  data  are  available,  and  risk  factors  for  CHC  development  remain  unresolved  
(33).  Older  donors,   corticosteroid   treatment   for  acute  cellular   rejection,  high   levels  of  HCV  
RNA  after  LT,  non-­C/C  recipient  IL-­28B  genotype  have  all  been  implicated  in  previous  reports  
(13).  HCV  quasispecies  were  also  implicated  in  the  pathogenesis  of  CHC,  with  contradictory  
results   (37-­40).   We   investigated   for   the   first   time,   using   a   high   sensitive   method,   HCV  
quasispecies  evolution  of  HCV  NS5B  region,  coding  for  the  HCV  polymerase,  in  patients  with  
CHC  compared  to  a  control  group.  We  showed  that  the  complexity  of  HCV  quasispecies  in  
pretransplant   serum   did   not   correlate   with   the   posttransplant   disease   course,   as   in   both  
groups,  CHC  and  control,  the  distribution  of  HCV  quasispecies  was  similar.  On  contrary,  after  
LT,   patients   with   CHC   presented   a   homogenization   of   HCV   quasispecies   of   NS5B,  more  
pronounced  than  patients  with  mild  HCV  recurrence  (whose  viral  quasispecies  had  a  greater  
post-­LT  quasispecies  complexity).  Messaguer  et  al.  (40)  previously  demonstrated  that  there  
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was  an  inverse  correlation  between  the  diversification  of  the  NS5B  region  and  the  severity  of  
liver  damage  during  the  first  year  after  LT.  They  showed  that  patients  with  mild  recurrence  had  
a   more   elevated   genetic   evolution   of   the   NS5B   region   along   with   lower   HCV-­RNA  
concentrations,  whereas  a  significant  proportion  of  patients  with  severe  histological  recurrence  
presented  high   levels  of   viremia  along  with   little  genetic  evolution  of  NS5B.  Another   study  
showed   that   the   degree   of   diversification   of   another   HCV   genome   region,   hypervariable  
region-­1  (HVR-­1)  of  the  HCV-­E2  domain,  was  inversely  correlated  with  the  severity  of  HCV  
recurrence   (39).   Sequencing   the   same  HCV   genome   region,   Pessoa   et   al.   (37)   found   no  
differences   in   terms   of   HCV   complexity   before   LT   between   patients   with   or   without   CHC;;  
however,  quasispecies  diversity  (inter-­sample  diversity)  was  greater  in  transplanted  patients  
over  time,  especially  in  those  with  severe  recurrent  disease.  Using  an  innovative  methodology,  
ultra-­deep  sequencing,  we  confirmed  and  expanded  on  the  previous  data.    
In  the  context  of  many  divergent  genomes  present  in  the  infecting  viral  quasispecies,  one  or  
a  few  viruses  may  outgrow  the  others  and  generate  a  relatively  uniform  quasispecies.  One  
can  argue  that  the  low  grade  genetic  evolution  of  NS5B  observed  in  CHC  might  be  related  to  
the  weak  immune  pressure  against  HCV  (34)  resulting  from  the  immunosuppressive  therapy.  
However,   we   did   not   show   any   significant   difference   between   the   two   groups   in   terms   of  
immunosuppression.  After  LT,  emerging  HCV  quasispecies   requires  adaptation   to   the  new  
graft,  and  those  propagated  viral  variants  that  most  efficiently  replicate  become  predominant  
(36).  In  addition,  new  mutants  with  increased  fitness  for  the  graft  may  emerge  and  compete  
with  pre-­LT  variants.    Supporting  the  latter,  we  found  that  the  master  sequence  present  before  
LT  propagated  in  most  of  CHC  patients  after  LT,  but  not  in  patients  with  mild  HCV  recurrence.  
Similarly,   using   a   different   method,   (HTA   and   nucleotide   sequencing)   Sullivan   et   al.   (38)  
demostrated  that  quasispecies  major  variants  present  in  pretransplant  serum  were  efficiently  
propagated  after  liver  transplantation  in  3  patients  with  severe  HCV  recurrence  but  not  in  the  
2   patients   with   mild   recurrence.   It   is   possible   that   some   circulating   viruses   in   the   initial  
 
33 
quasispecies  after  LT  were  defective  and  only  a  very  small  proportion  of  the  viruses  had  the  
capability  of  initiating  infection  of  the  graft.  Indeed,  we  identified  specific  mutations  in  patients  
with  CHC,  but  our  sample  sized  did  not  allow  to  prove  a  distinct  pattern  between  both  groups  
of  patients.  We  cannot  exclude  that  some  specific  strains  have  a  higher  pathogenic  potential  
than   others,   due   to   the   presence   of   the   above-­mentioned  mutations   Importantly,   patients  
included  in  this  study  were  at  the  extreme  spectrum  of  hepatitis  C  recurrence:  mild  disease  
(individuals  with  an  excellent  long-­term  outcome)  and  patients  with  CHC.  In  the  latter  group,  
viral   load  was   extremely   high   (and   significantly   different   than   in   control   patients).   Thus,   it  
appears   that   the   virus   infecting   the   graft   from   patients   with   CHC   had   a   clear   replication  
advantage.   Nevertheless,   to   prove   this   hypothesis   we   would   need   to   incorporate   such  
mutations   in   subgenomic   replicons   or   full-­length   HCV   isolates   and   demonstrate   a   high  
replication  capacity.      
  
In   conclusion,  despite   the  high  efficacy  of  DAAs-­based  antiviral   treatment   in  HCV-­infected  
patients   awaiting   LT,   we   showed   persistence   of   HCV-­RNA   in   the   liver   explant   of   a   high  
proportion   patients.   This,   however,   does   not   seem   to   impact   on   posttransplant   HCV  
recurrence,   except   for   patients  with   high   explant  HCV-­RNA   concentrations.  We   showed   a  
downregulation   of   IFN-­signaling   in   patients   treated   with   DAAs   awaiting   a   LT,   that   could  
explain,  at  least  in  part,  some  cases  of  HCV  recurrence.  
In  patients  who  develop  a  cholestatic  hepatitis  C  (CHC)  recurrence  after  LT  the  virus  replicates  
at  high  level  in  the  graft.  We  found  that  the  master  sequence  present  before  LT  propagated  in  
most   of   CHC   patients   after   LT,   but   not   in   patients   with   mild   HCV   recurrence.   The   latter  
supports  a  replication  advantage  in  the  viral  quasispecies  of  patients  with  CHC.  We  identified  
some  specific  NS5B  mutations  in  virus  genome  of  patients  with  CHC,  which  could  explain  a  
greater  pathogenic  potential.  In  order  to  demonstrate  this  hypothesis,  the  next  step  should  be  











Table  1.  Clinical  and  virological  characteristics  of  patients  treated  with  an  IFN-­free  regimen  
(n=39)  on  the  waiting  liver  for  liver  transplantation  (n=39),  comparing  those  with  and  those  
without  detectable  HCV-­RNA  in  liver  explant,  by  univariate  analysis.  Categorical  variables  








































Gender  (male)   28  (72%)   9  (69%)   19  (73%)   0.801  
Age  (years)   58  (55-­62)   61  (55-­63)   57  (55-­59)   0.189  
BMI   27  (24-­31)   26  (22-­31)   27  (25-­32)   0.432  
Treatment  duration  [weeks]   17  (13-­24)   21  (16-­26)   14  (10-­22)   0.014  
Time  prior  LT  with  serum  RNA  
negative  [days]     77  (46-­122)   99  (76-­171)   61  (15-­118)   0.013  
Viral  load  at  baseline  [Log  
IU/L]  
6.1  (5.6-­6.5)   6  (5.8-­6.7)   6  (5.6-­6.5)   0.988  
Genotype  G1  
        GT1a  
        GT1b  
        GT2  
        GT3  




















IL28B  CT/TT   27  (75%)   9  (82%)   18  (72%)   0.531  
ALT  at  baseline  (IU/L)   79  (45-­96)   83  (68-­106)   70  (43-­92)   0.250  


















MELD  before  treatment   9  (7-­11)   9  (7-­10)   10  (8-­11)   0.143  
HCV-­RNA  TND  at  W2   7  (20%)   3  (30%)   4  (16%)   0.350  
HCV-­RNA  TND  at  W3   21  (70%)   7  (70%)   14  (70%)   1.00  
HCV-­RNA  TND  at  W4   24  (68%)   6  (60%)   18  (72%)   0.490  
MxA  (fold-­change)   1.8  (1.3-­3.5)   2.06  (1.3-­3)   1.73  (1.5-­4)   0.611  






Table  2.  Clinical  and  virological  characteristics  the  26  patients  with  an  HCV-­RNA  
positive  liver  explant  comparing  those  who  achieved  pTVR  and  those  who  relapsed,  
by  univariate  analysis.  Categorical  variables  are  shown  as  n  (%)  and  quantitative  

























Gender  (male)   17  (77%)   2  (50%)   0.258  
Age  (years)   57  (55-­59)   57  (53-­62)   0.948  
BMI   27  (24-­31)   27  (25-­31)   0.882  
Treatment  duration  [weeks]   15  (11-­23)   10  (4-­22)   0.481  
Time  prior  LT  with  serum  RNA  
negative  [days]  
64  (34-­121)   14  (13-­74)   0.201  
Viral  load  at  baseline  [Log  IU/L]   6  (5.6-­6.4)   6  (5.3-­6.7)   0.887  
Copies  HCV-­RNA/reaction   3  (1.7-­5.9)   23  (8.6-­69)   0.016  
Genotype  G1   18  (82%)   4  (100%)   0.354  
IL28B  CT/TT   14  (67%)   4  (100%)   0.174  
ALT  at  baseline  (IU/L)   72  (54-­92)   43  (36-­97)   0.266  
MELD  at  baseline   11  (8-­13)   8  (7-­10)   0.201  
Child-­Pugh   6  (5-­8)   6  (5-­7)   0.423  
HCV-­RNA  TND  at  W2   19  (90%)   2  (50%)   0.106  
HCV-­RNA  TND  at  W3   10  (62%)   4  (100%)   0.143  
HCV-­RNA  TND  at  W4   14  (67%)   4  (100%)   0.174  
OAS   10  (7-­18)   12  (10-­15)   0.510  


















Recipient  gender  (male)   9  (69%)   7  (78%)   0.627  
Recipient  age  (years)   61  (51-­66)   50  (47-­56)   0.056  
Donor  age  (years)   62  (45-­65)   35  (28-­49)   0.003  
HCV  genotype  (G1)   11  (84%)   7  (77%)   0.368  
Recipient  IL28B  (CC)   1  (7%)   3  (33%)   0.091  
Immunosuppression  (TAC)   10  (76%)   4  (44%)   0.199  
Acute  rejection   0  (0%)   3  (33%)   0.050  
Viral  load  before  LT  (log  IU/L)   5.6  (5-­6)   5.5  (5-­5.7)   0.720  
Viral  load  after  LT  (log  IU/L)   8  (7.7-­8)   5.6  (5.6-­6.4)   0.002  
GGT  (IU/L)   1513  (765-­2708)   216  (23-­520)   <0.001  
AP  (IU/L)   860  (553-­1141)   255  (153-­358)   <0.001  
Bilirubin  (ug/mL)   6.4  (3.5-­16)   1.1  (0.6-­1.4)   0.001  
  
Table   3.   Clinical   and   virological   characteristics   of   patients,   comparing  
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Figure  2.  Expression  of  OAS1  (A)  and  MxA  (B)  RNA  in  liver  explants  of  different  groups  
of   patients:   individuals   undergoing   interferon-­based   therapy   and   serum   HCV-­RNA  
undetectable  (sRNA-­  IFN-­based),  patients  with  positive  HCV-­RNA  in  serum  (sRNA+)  
and  patients  undergoing  an   IFN-­free   regimen  and  undetectable  HCV-­RNA   in  serum  
(sRNA  IFN-­free).  The  amount  of  OAS1  and  MxA  RNA  are  depicted  in  the  y  axis  as  fold-­
change  in  comparison  to  the  reference  RNA  and  corrected  to  the  endogenous  control  


















Figure   3.   Expression   of   OAS1   (A)   and   MxA   (B)   RNA   in   liver   explants   of   patients  
undergoing  IFN-­free  therapy  and  undetectable  serum  HCV-­RNA,  comparing  those  with  
an  HCV-­RNA  positive  and  with  a  negative  liver  explant.  The  amount  of  OAS1  and  MxA  
RNA  are  depicted  in  the  y  axis  as  fold-­change  in  comparison  to  the  reference  RNA  and  


































Figure   4.   Pattern   of   specific   emergent   amino   acid   substitutions  within   the  NS5B  
region,  at  baseline  and  at   time  of   relapse,  by  population  sequencing  and  UDPS,  
present   in  patients  with  positive   (red  group)  or  negative   (green  group)  HCV-­RNA  







































































Figure  5a.  HCV  quasispecies  genetic  diversity  at  the  moment  of  liver  















Figure  5b.  HCV  quasispecies  mutation  frequency  at  the  moment  of  liver  
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Figure  6.  HCV  quasispecies  genetic  diversity  before  and  after  liver  transplantation  













Figure   7.   HCV   quasispecies   mutation   frequency   before   and   after   liver  
















































Figure  8a.  Phylogenetic   tree  of  NS5B  master   sequence  before  and  after   liver  
transplantation  (LT),  in  patients  with  cholestatic  HCV    
*The  green  lines  indicate  those  patients  with  the  same  master  sequence  before  and  after  
LT.    
  
























































Gen	  1a	  	  	  	  	  	  	  	  	  	  	    





























Figure  8b.  Phylogenetic  tree  of  NS5B  master  sequence  before  and  after  liver  
transplantation  (LT),  in  patients  with  mild  HCV  recurrence  (control  group).    
*The  green  lines  indicate  those  patients  with  the  same  master  sequence  before  and  
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Figure   9.   Frequency   of   mutations   present   in   specific   polymorphic   sites  
determined   comparing   all   sequences   (pre   and   post-­transplant)   of   two  
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